OUR
Recent Articles
Looking back at the past decade, in 2013, filings of patent lawsuits in the United States were at an...
Australia stands apart from many other key jurisdictions in allowing first and second medical use claims...
FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas Pharma Inc. v Akebia Therapeutics...
When evaluating the novelty of claims in life sciences and pharmaceutical, compared with EPO, the examination...
Keep up with your IP – a global look at filing life sciences patents
The Patent Lawyer Magazine – FILING LIFE SCIENCES PATENTS ;
azami
July 28, 2022
Patent Filing Litigations Continue to Increase Despite the COVID-19 Pandemic
Looking back at the past decade, in 2013, filings of
azami
February 2, 2022
Getting the Most from Medical-Use Claims in Australia
Australia stands apart from many other key jurisdictions in allowing
azami
December 2, 2021
Insufficiency after FibroGen v Akebia: A New Approach
FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas
azami
December 2, 2021
Patent Examination Practice for Novelty in the Field of Life Sciences in China
When evaluating the novelty of claims in life sciences and
azami
December 1, 2021
Notes to Patent Drafters: Common Issues with Broad Specifications in Canada
The Canadian Patent Act imposes an unyielding relationship between the requirement for
azami
December 1, 2021
Get our insights delivered straight to your inbox.
